Oncology - Next-Generation Therapies with Differentiated Science
Our Oncology portfolio is focused on advancing differentiated, science-led therapies across solid tumors and hematological malignancies, where disease complexity and unmet medical need continue to challenge existing treatment options. The approach combines deep disease understanding, disciplined science, and global partnerships to support the development of differentiated therapies with meaningful clinical relevance.
Our capabilities are strengthened through Ichnos Glenmark Innovation (IGI), which contributes specialised expertise in biologics discovery and early development within the broader oncology ecosystem. A flagship programme within this portfolio is ISB 2001, a first-in-class trispecific antibody being developed for the treatment of multiple myeloma. The programme is currently in early clinical development and is being advanced through a global partnership with AbbVie, providing strong external validation of the underlying science and approach.
Complementing biologic innovation, the oncology portfolio also includes advanced immunotherapies and targeted treatments developed through strategic global partnerships. These include Envafolimab (QinHayo®), Tislelizumab (TEVIMBRA®), Zanubrutinib (Brukinsa®), Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC), Aumolertinib – a third-generation EGFR-TKI, among others.
Together, these partnerships expand access to advanced immunotherapies, targeted treatments, and emerging modalities such as antibody drug conjugates (ADCs), enabling a broader and more differentiated oncology offering across solid tumours and hematological malignancies.
Our footprint in Oncology reflects the convergence of science, collaborations and purpose –
backed by longstanding R&D, a diversified portfolio, and partnerships that expand global reach.
2
Decades of research in cancer care
5
Strategic collaborations
